News | Imaging Software Development | August 29, 2025

HeartFocus Introduces First U.S. Clinical Product on Butterfly Network

FDA-cleared AI-guided cardiac imaging software now available for all U.S healthcare professionals.

HeartFocus Introduces First U.S. Clinical Product on Butterfly Network

Aug. 27, 2025 – HeartFocus, the AI-enabled cardiac imaging software developed by data-driven medtech company DESKi, announced its U.S. commercial launch. HeartFocus will initially be available on Butterfly Network’s handheld ultrasound devices, the FDA-cleared software enables any healthcare professional to conduct diagnostic-quality heart ultrasounds after just hours of training. Health systems, primary care clinics, and clinical education institutions can now access the application. 

Following recent FDA clearance and a successful international clinical trial, HeartFocus has moved from pilot to full deployment, empowering healthcare professionals to conduct fast and comprehensive cardiac assessments anywhere patients are seen, from rural clinics to primary care, education, cardiology, and even in acute high-volume triage environments.

HeartFocus addresses the most persistent barriers in cardiac care: limited access to trained sonographers and long wait times for diagnostic imaging. With just hours of training, any healthcare professional using HeartFocus can capture comprehensive echocardiographic views with consistency that has been clinically proven to match expert operators. Now commercially available through Butterfly Network’s single-probe, whole-body ultrasound system, providing seamless AI integration.

Bertrand Moal, PhD, MD, CEO of DESKi said, “With HeartFocus, we’re unlocking access to life-saving heart scans wherever they’re needed most. This isn’t just a product launch, it represents phase one in our mission to transform how and where cardiac care is delivered, setting a new standard in accessibility and impact.”

Davinder Ramsingh, VP, Innovation Partnerships and Clinical Development at Butterfly Network, said, “This commercial launch marks a first within the Butterfly Garden, offering deep integration with one of the most widely adopted handheld ultrasound systems in the U.S. We’re thrilled to bring HeartFocus to healthcare professionals nationwide. By combining Butterfly’s handheld device with HeartFocus’ AI-powered software, we’re enabling earlier detection and better outcomes, from large health systems to rural, underserved communities.”

Now addressing increasing cardiac care needs, HeartFocus empowers providers of all levels to deliver timely, high-quality cardiac care, anywhere it’s needed.

To learn more, visit www.heartfocus.ai 


Related Content

News | FDA

Jan. 13, 2026 – Innovative Health, Inc. has received its 50th clearance from FDA to reprocess single-use medical devices ...

Home January 15, 2026
Home
News | FDA

Jan. 12, 2026 — HeartLung Corp. has announced U.S. Food and Drug Administration (FDA) clearance of AI-CVD, its AI ...

Home January 12, 2026
Home
News | FDA

Jan. 6, 2026 — W. L. Gore & Associates’ medical business (Gore) has announced the FDA approval of the Gore Viabahn ...

Home January 06, 2026
Home
News | FDA

Dec. 22, 2025 — Abbott recently announced the U.S. Food and Drug Administration (FDA) has approved the company's Volt ...

Home January 05, 2026
Home
News | FDA

Dec. 18, 2025 — Huxley Medical has announced the SANSA home sleep apnea test has received regulatory clearance from the ...

Home December 19, 2025
Home
News | FDA

Dec. 18, 2025 — Abbott has received U.S. Food and Drug Administration (FDA) clearance and CE Mark for its Amplatzer ...

Home December 18, 2025
Home
News | FDA

Dec. 15, 2025 — HeartSciences Inc., a healthcare information technology company advancing the use of ECG/EKGs through ...

Home December 16, 2025
Home
News | FDA

Nov. 25, 2025 — Remington Medical has received U.S. Food and Drug Administration (FDA) 510(k) clearance and announced ...

Home December 09, 2025
Home
News | FDA

Dec. 3, 2025 — Atraverse Medical, a medical device company developing next-generation left-heart access technology, has ...

Home December 05, 2025
Home
News | FDA

Dec.1, 2025 – MannKind Corp. has announced that the U.S. Food and Drug Administration (FDA) has accepted the sNDA ...

Home December 01, 2025
Home
Subscribe Now